Live Breaking News & Updates on Bliss Bio Health

Stay updated with breaking news from Bliss bio health. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Cellectar Biosciences Reports Financial Results for Year

Management to host a conference call today at 8:30 am ET. ....

United States , James Caruso , Cellectar Biosciences , Claire Lacagnina , Development Expense , Bliss Bio Health , Cellectar Biosciences Inc , Exchange Commission , Recent Corporate , Rosalind Advisors , Cash Equivalents , Administrative Expense , Eastern Time , Phospholipid Drug Conjugate , Ended December , Nasdaq Clrb , Cellectar Biosciences ,

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

FLORHAM PARK, N.J., March 27, 2024 Cellectar Biosciences, Inc. , a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the. ....

United States , Cellectar Biosciences , James Caruso , Claire Lacagnina , Bliss Bio Health , Cellectar Biosciences Inc , Development Expense , Globenewswire Inc , Exchange Commission , Recent Corporate , Cash Equivalents , Administrative Expense , Eastern Time , Phospholipid Drug Conjugate ,

Cellectar Biosciences to Present at the Oppenheimer 34th

FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused. ....

Cellectar Biosciences , James Caruso , Claire Lacagnina , Bliss Bio Health , Cellectar Biosciences Inc , Healthcare Life Sciences Conference , Annual Healthcare Life Sciences Conference , Phospholipid Drug Conjugate , Nasdaq Clrb , Cellectar Biosciences ,

Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study

FLORHAM PARK, N.J., Jan. 30, 2024 Cellectar Biosciences, Inc. , a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the. ....

United States , Sameer Farouk Sait , James Caruso , Claire Lacagnina , Cellectar Biosciences , Exchange Commission , National Cancer Institute , Globenewswire Inc , Bliss Bio Health , Cellectar Biosciences Inc , Memorial Sloan Kettering Cancer Center , National Institute Of Health , Farouk Sait , Sloan Kettering Cancer , Bing Neel Syndrome , Fast Track , Cancer Institute , Pediatric High Grade Gliomas , Phospholipid Drug Conjugate ,

Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million

FLORHAM PARK, N.J., Jan. 25, 2024 Cellectar Biosciences, Inc. , a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the. ....

United States , Cellectar Biosciences , James Caruso , Claire Lacagnina , Exchange Commission , Cellectar Biosciences Inc , Globenewswire Inc , Bliss Bio Health , New Drug Application , Phospholipid Drug Conjugate ,